SESN
$1.15
Sesen Bio
($.10)
(8.00%)
SESN
Earnings Whisper ®
N/A
3rd Quarter September 2021
Consensus:  ($0.06)
Revenue:  $0.53 Mil
Monday
Nov 8
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SESN reports earnings?
Beat
Meet
Miss

Where is SESN's stock price going from here?
Up
Flat
Down
Stock chart of SESN
Analysts
Summary of analysts' recommendations for SESN
Score
Grade
Pivots
Resistance
$1.32
$1.28
$1.21

$1.17

Support
$1.10
$1.06
$0.99
Tweet
Growth
Description
Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven Biotherapeutics, is based in Massachusetts, United States.